These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25142297)

  • 1. Facial Angiofibroma Severity Index (FASI): reliability assessment of a new tool developed to measure severity and responsiveness to therapy in tuberous sclerosis-associated facial angiofibroma.
    Salido-Vallejo R; Ruano J; Garnacho-Saucedo G; Godoy-Gijón E; Llorca D; Gómez-Fernández C; Moreno-Giménez JC
    Clin Exp Dermatol; 2014 Dec; 39(8):888-93. PubMed ID: 25142297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
    Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
    Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
    Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
    Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
    Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
    Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
    Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
    Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex.
    Hamada I; Yukutake Y; Morita Y; Ishikawa N; Shimizu K; Wataya-Kaneda M
    J Dermatol; 2024 Jun; 51(6):752-758. PubMed ID: 38619178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
    Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
    JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.
    Salido R; Garnacho-Saucedo G; Cuevas-Asencio I; Ruano J; Galán-Gutierrez M; Vélez A; Moreno-Giménez JC
    J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1315-8. PubMed ID: 21834948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin.
    Kaufman McNamara E; Curtis AR; Fleischer AB
    J Dermatolog Treat; 2012 Feb; 23(1):46-8. PubMed ID: 20673154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
    Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
    JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
    Wheless JW; Almoazen H
    J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.
    Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
    Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
    Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment of disfiguring facial angiofibromas in tuberous sclerosis complex with surgical debulking and topical sirolimus.
    Patterson JL; Iyengar S; Catasus C; Kolodney JA; Zinn Z
    Cutis; 2020 Dec; 106(6):307-308. PubMed ID: 33471874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
    Haemel AK; O'Brian AL; Teng JM
    Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030
    [No Abstract]   [Full Text] [Related]  

  • 16. Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex.
    Hatano T; Ohno Y; Imai Y; Moritake J; Endo K; Tamari M; Egawa S
    Orphanet J Rare Dis; 2020 Jun; 15(1):133. PubMed ID: 32487130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial.
    Chen PL; Hong JB; Shen LJ; Chen YT; Wang SJ; Liao YH
    Br J Dermatol; 2020 Oct; 183(4):655-663. PubMed ID: 32064596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
    Boggarapu S; Roberds SL; Nakagawa J; Beresford E
    Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted topical and combination laser surgery for the treatment of angiofibromas.
    Bae-Harboe YS; Geronemus RG
    Lasers Surg Med; 2013 Nov; 45(9):555-7. PubMed ID: 24136238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
    Foster RS; Bint LJ; Halbert AR
    Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.